Page last updated: 2024-11-13

kuraridin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

kuraridin: isolated from Sophora flavescens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
SophoragenusA plant genus of the family FABACEAE.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID44428631
CHEMBL ID243362
MeSH IDM0553342

Synonyms (18)

Synonym
kuraridin
CHEMBL243362
kuraidin
bdbm50366787
kuraridine
34981-25-4
PIAPWPAWQGDOMN-SXAWMYDMSA-N
MS-27861
GLXC-17536
HY-121381
DTXSID501319126
CS-0081833
AKOS040761957
2-propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-[5-methyl-2-(1-methylethenyl)-4-hexenyl]phenyl]-3-(2,4-dihydroxyphenyl)-, (e)-(+)-
2,2',4,4'-tetrahydroxy-6'-methoxy-3'-(5-methyl-2-isopropenylhex-4-enyl)chalcone
Z399B8AG6Z
2-propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-[(2r)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]phenyl]-3-(2,4-dihydroxyphenyl)-, (2e)-
(2e)-1-[2,4-dihydroxy-6-methoxy-3-[(2r)-5-methyl-2-(1-methylethenyl)-4-hexen-1-yl]phenyl]-3-(2,4-dihydroxyphenyl)-2-propen-1-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cGMP-specific 3',5'-cyclic phosphodiesteraseRattus norvegicus (Norway rat)IC50 (µMol)0.64000.00031.35116.1000AID158109
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Rattus norvegicus (Norway rat)IC50 (µMol)8.27000.00032.723210.0000AID160105
cAMP-specific 3',5'-cyclic phosphodiesterase 4CRattus norvegicus (Norway rat)IC50 (µMol)8.27000.00032.723210.0000AID160105
cAMP-specific 3',5'-cyclic phosphodiesterase 4BRattus norvegicus (Norway rat)IC50 (µMol)8.27000.00032.663810.0000AID160105
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)0.60000.00021.557410.0000AID403341
cAMP-specific 3',5'-cyclic phosphodiesterase 4ARattus norvegicus (Norway rat)IC50 (µMol)8.27000.00032.723210.0000AID160105
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID295283Inhibition of human SGLT1 expressed in COS1 cells assessed as [14C]methyl-alpha-D-glucopyranoside uptake at 50 uM2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens.
AID403549Antiviral activity against HSV1 in african green monkey Vero cells assessed as virus-induced cytopathic effect after 3 days by MTT assay1998Journal of natural products, Dec, Volume: 61, Issue:12
A new prenylated flavonol from the roots of Sophora flavescens.
AID160123Relative inhibition of Phosphodiesterase 4 and Phosphodiesterase 52002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
AID158109Inhibition of Phosphodiesterase 5 from rat diaphragm2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
AID160105Inhibition of Phosphodiesterase 4 from rat liver2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
AID403550Antiviral activity against HSV2 in african green monkey Vero cells assessed as virus-induced cytopathic effect after 3 days by MTT assay1998Journal of natural products, Dec, Volume: 61, Issue:12
A new prenylated flavonol from the roots of Sophora flavescens.
AID295284Inhibition of human SGLT2 expressed in COS1 cells assessed as [14C]methyl-alpha-D-glucopyranoside uptake at 50 uM2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens.
AID403341Inhibition of COX12005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID159373Inhibition of Phosphodiesterase 3 from rat diaphragm2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
AID159374Relative inhibition of Phosphodiesterase 3 and Phosphodiesterase 52002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (8.33)18.2507
2000's3 (25.00)29.6817
2010's8 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]